Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  • Pascual-García, Mónica
  • Bonfill-Teixidor, Ester
  • Planas-Rigol, Ester
  • Rubio-Perez, Carlota
  • Iurlaro, Raffaella
  • Arias, Alexandra
  • Cuartas, Isabel
  • Sala-Hojman, Ada
  • Escudero, Laura
  • Martínez-Ricarte, Francisco
  • Huber-Ruano, Isabel
  • Nuciforo, Paolo
  • Pedrosa, Leire
  • Marques, Carolina
  • Braña, Irene
  • Garralda, Elena
  • Vieito, María
  • Squatrito, Massimo
  • Pineda, Estela
  • Graus, Francesc
  • Espejo, Carmen
  • Sahuquillo, Juan
  • Tabernero, Josep
  • Seoane, Joan
Cancer response to immunotherapy depends on the infiltration of CD8+ T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8+ T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8+ T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

  • Annibali, Daniela
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Favuzzi, Emilia
  • Jauset González, Toni|||0000-0003-2869-5804
  • Serrano, Erika
  • Cuartas, Isabel
  • Redondo Campos, Sara
  • Folch, Gerard
  • Gonzàlez-Juncà, Alba
  • Sodir, Nicole M.
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Swigart, Lamorna B.
  • Mc Gee, Margaret M.
  • Somma, Maria Patrizia
  • Nasi, Sergio
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Evan, Gerard I.|||0000-0003-0412-1216
  • Soucek, Laura|||0000-0002-4750-7971
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. Using the Myc dominant negative Omomyc, we previously showed that Myc inhibition is a promising strategy for cancer therapy. Here, we preclinically validate Myc inhibition as a therapeutic strategy in mouse and human glioma, using a mouse model of spontaneous multifocal invasive astrocytoma and its derived neuroprogenitors, human glioblastoma cell lines, and patient-derived tumours both in vitro and in orthotopic xenografts. Across all these experimental models we find that Myc inhibition reduces proliferation, increases apoptosis and remarkably, elicits the formation of multinucleated cells that then arrest or die by mitotic catastrophe, revealing a new role for Myc in the proficient division of glioma cells. Myc has been implicated in the development of multiple types of cancer. Here, the authors explore the therapeutic potential and mechanism of action of Myc inhibition in mouse and human models of glioblastoma, an aggressive type of tumour that is often resistant to conventional therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Bonfill-Teixidor, Ester|||0000-0002-9260-448X
  • Planas-Rigol, Ester|||0000-0001-5948-2241
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Iurlaro, Raffaella|||0000-0003-1019-6679
  • Arias, Alexandra
  • Cuartas, Isabel
  • Sala-Hojman, Ada
  • Escudero, Laura|||0000-0001-7385-673X
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Huber-Ruano, Isabel
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Marques, Carlota|||0000-0002-8308-5630
  • Braña, Irene|||0000-0002-1068-9601
  • Garralda, Elena|||0000-0002-4412-7842
  • Vieito, María|||0000-0001-7531-343X
  • Squatrito, Juan|||0000-0002-4593-3790
  • Pineda, Estela|||0000-0003-2128-747X
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Espejo, Carmen|||0000-0001-9949-5901
  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Tabernero, Josep|||0000-0002-2495-8139
  • Seoane Suárez, Joan|||0000-0002-6541-5974
Cancer response to immunotherapy depends on the infiltration of CD8 T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8 T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8 T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.